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ABSTRACT 
Pediatric obesity is an important public health problem nowadays. Portugal is no exception, being one third of 
children and adolescent either overweight or obese. The behavioral approach is the basilar stone of obese 
treatment nowadays. It focuses in change lifestyle, substituting unhealthy habits by new, healthier, ones. A 
great number of strategies have been studied to try to respond to this growing problem, with varying results. 
The heterogeneity present in the scientific literature is likely to be explained by different study designs and 
targeted populations. Nevertheless, the results, in general, support that improvements in diet and increase in 
physical exercise pattern are associated with improvements in risk factors for cardiovascular disease, namely 
an atherogenic lipid profile, insulin resistance and inflammation, besides the reduction in adiposity itself. The 
combination of diet and exercise in the same intervention appear to be beneficial and complementary. 
However, different types of diet and exercise might lead to different results. The use of pharmacological 
adjuvants in pediatric obesity treatment is very limited in clinical practice due, mainly, to the lack of adequate 
studies; However some options have demonstrated to contribute to a small, but consistent, improvement in 
adiposity. Surgery, on the other hand, is the last therapeutic option and should be considered only in the more 
severe cases. Pediatric obesity tends to track until adulthood, and is associated with increased risk of 
cardiovascular disease in the future. Acting as early as possible in an individual life, when health habits are 
easier to acquire, and likelier to be kept, is crucial. Governments, including the Portuguese, have been paying 
more attention to this issue in the last years. However, much more can be made in general policies to create a 
less obesogenic environment and make the healthy choices the easier ones. 
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RESUMO 
A obesidade pediátrica é atualmente um problema de saúde pública crescente. Portugal não é exceção sendo 
que um terço da população pediátrica apresenta excesso de peso ou mesmo obesidade. A abordagem 
comportamental é a pedra basilar dos tratamentos da obesidade, focando-se em alterações do estilo de vida e 
substituição de hábitos nefastos por outros saudáveis. Um elevado número de estratégias foram estudadas 
para responder a este problema crescente apresentando, contudo, resultados variáveis. A heterogeneidade de 
resultados apresentada na literatura científica pode ser explicada por diferentes desenhos de estudo e de 
populações alvo. Não obstante, os resultados apontam no sentido de que melhorias na dieta e no padrão de 
atividade física estão associados com melhorias nos fatores de risco cardiovascular, nomeadamente do perfil 
aterogénico lipídico, resistência à insulina, inflamação, para além da redução da própria adiposidade. A 
combinação de dieta e exercício na mesma intervenção parece ser benéfica e complementar. No entanto, 
diferentes tipos de atividade física e de dieta podem levar a resultados diferentes. O uso de adjuvantes 
farmacológicos no tratamento da obesidade pediátrica é altamente limitado na prática clínica, especialmente 
devido à falta de estudos adequados; contudo algumas opções demonstraram contribuir para uma pequena 
mas consistente melhoria da adiposidade. A cirurgia é uma solução de último recurso e para casos extremos. A 
obesidade pediátrica tende a manter-se até à idade adulta e está associada a um aumento do risco 
cardiovascular futuro. Uma atuação tão precoce quanto possível, quando é mais fácil a aquisição de hábitos 
adequados, é crucial. Os governos estão a prestar cada vez mais atenção a este assunto. Contudo, muito mais 
pode ser feito em termos de políticas globais, no sentido de criar um ambiente menos propício à obesidade e 
favorável à escolha de opções mais saudáveis. 
Palavras-chave: Obesidade pediátrica, intervenção, doença cardiovascular 
 
 
1Biological Science Department, Faculty of Pharmacy, University of Porto, Porto, Portugal. 
2Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal. 
3Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal. 
Endereço para correspondência: Luís Filipe Amado Belo, Departamento de Ciências Biológicas, Faculdade de 
Farmácia da Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal. Email: 
luisbelo@ff.up.pt 
Submetido/ Submitted: 16 de abril de 2014| Aceite/Accepted: 12 de maio de 2014 
© Ordem dos Farmacêuticos, SRP  ISSN: 2182-334 
Nascimento H., Quintanilha A., Santos-Silva A., Belo L. 
70 
INTRODUCTION 
Obesity is increasing worldwide in recent 
years, both in developed and in developing 
countries, leading many authors to refer to 
obesity as the pandemia of the 21st century. 
In fact, obesity is now considered as a 
disease with its own complexity, and has 
been deeply studied in the last years. The 
modern lifestyle, characterized by increased 
energy intake and reduced energy 
expenditure, is at the basis of the obesity 
phenomena1. 
Pediatric obesity is accompanying the 
adult trend and has reached high rates in 
many countries. In Portugal around one third 
of the children are overweight or obese2,3. 
The use of therapeutic strategies for 
tackling obesity in pediatric ages aims at 
weight normalization and reduction of the 
future risk of cardiovascular disease (CVD). A 
behavioral approach, towards lifestyle 
modification, is the main pillar of obesity 
treatment, both in children and adults. The 
main objectives are to increase physical 
activity and improve diet in order to improve 
the energy balance. Two strategies are 
usually used: non-interventional programs, 
involving nutritional counseling and 
motivation to exercise; and interventional 
programs, involving the use of diets and/or 
physical exercise programs. Pharmacological 
drugs have also been tested as adjuvants in 
the treatment, with limited but consistent 
results4-7. 
Usually, childhood obesity is treated by a 
regular pediatrician. As obesity increases, 
and comorbidities or psychological conse-
quences appear, a multidisciplinary approach 
becomes necessary, including a nutritionist, a 
behavior modification specialist, a psycho-
logist and an obesity specialist pediatrician4-7. 
The treatment of obesity is a long process 
presenting different phases that should not 
be hurried. In the beginning of the 
treatment, several visits might be necessary, 
to build the trust between the doctor/team 
and the child. It is beneficial for the children 
to be followed by the same doctor 
throughout the treatment8. 
By improving weight other metabolic 
derangements present in obesity also tend to 
improve. The International Diabetes Fede-
ration (IDF) 2007 recommendations for the 
prevention and treatment of metabolic 
syndrome (MS) in children and adolescents, 
for example, focus on weight improvement 
and management, thus, tackling obesity as a 
MS underlying cause. IDF recommendations 
are not much different from other 
organizations such as the World Health 
Organization (WHO), the American Asso-
ciation of Pediatricians (AAP), and the 
Associacíon Española de Pediatría (AEP)4,6,9,10. 
Obesity reduction programs in children 
should be adapted to age, degree of obesity 
and presence (or not) of comorbidities. The 
treatment should start immediately and not 
wait for older ages4,6,8,11. Children and young 
adolescents have a linear growth potential 
that can help on body mass index (BMI) 
normalization and should be considered 
when defining a treatment strategy4,7,8. 
Depending on the age and the levels of 
adiposity, children with a BMI higher than 
the 85th percentile and lower than the 95th 
percentile (overweight children), or above 
95th percentile but without comorbidities 
(obese children without complications), 
could follow 3 basic options6,7,11: 
● Slow the rate of weight gain – used in 
very young children (2-4 years old), as 
they present a very rapid growth rate 
that might lead to BMI normalization; 
● Weight maintenance – used for chil-
dren over 4 years; 
● Gradual weight loss (1 to 2 kg/month) 
to improve BMI, in older children and 
adolescents. 
For children with BMI above the 95th 
percentile with comorbidities, an approach 
based on the severity of the situation should 
be used. Weight loss is usually necessary but, 
even in severe obesity, the weight loss 
program should be gradual for several 
reasons7,8,11,12: 
● It should be used a goal that the 
children can achieve to avoid 
demotivation; 
● Even slow weight gain involves a great 
reduction on habitual caloric intake, 
especially if the children is still 
growing; 
● Treatment of weight excess is a long 
term process and gradual weight loss 
is easier to be sustained for longer 
periods; 
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● Even small improvements of adiposity 
markers are already associated with a 
reduction of CVD risk factors (e.g. 
atherogenic lipid profile). 
Adolescents who have reached growth 
limit and have a BMI higher than 30 Kg/m2 
should be submitted to a program similar to 
that used for obese adults, to minimize CVD 
risk5,11. 
It is necessary to approach the 
child/adolescent in his culture, social and 
family environment, as it would be harder to 
tackle childhood obesity without the help of 
parents and care-takers5-7,11,13. 
The Portuguese National Child and 
Adolescent Health Program (NCAHP) provide 
guide-lines and check points to follow the 
pediatric development that, if correctly 
followed, might help to identify obesity and 
associated comorbidities while still in early 
stages, when the chances for a successful 
treatment are higher14. It also focuses on the 
promotion of healthy lifestyle habits, 
improving diet and increasing physical 
activity. A gradual responsabilization, first of 
the parents and, afterwards, of the 
child/adolescent, by their health main-
tenance and success of therapy should be 
done14. 
In Portugal, there are no clear guidelines 
on how the pediatric obesity should be 
approached, only general recommendations 
are given for a healthier lifestyle. 
Nevertheless, many hospitals in Portugal 
have specialized pediatricians and provide 
obesity appointments to which children can 
be referred. The obese appointments usually 
involve, besides the medical doctor, a visit to 
a nutritionist. 
Clearer guidelines regarding obesity and 
overweight treatment and prevention should 
be provided worldwide, and particularly in 
Portugal. It seems unreasonable that the 
NCAHP focus on dyslipidemia, hypertension 
and oral health programs, known 
comorbidities of obesity, while obesity is 
only referred twice along the 121 pages of 
the document. 
In this paper we aim to shortly review 
some therapeutic strategies regarding 
pediatric obesity and the influence of those 
therapeutic options in the reduction of 
cardiovascular risk factors. 
DIET 
Unbalanced diet and increased energy 
intake is a common problem nowadays and a 
major contributor to the epidemic obesity. A 
healthy diet is more expensive than other 
unhealthy options, creating a problem for 
lower income families5,10,11. 
Some interventional programs, in order to 
better control energy intake, choose to 
provide at least one balanced meal per day. 
Although this is a good strategy, it has the 
predictable logistic, children compliance and 
financial problems, particularly in longer 
studies9. 
To design a healthy diet the children’s 
nutritional habits and their socio-cultural 
reality should be considered. The basic idea 
of the diet in the obese pediatric patient is to 
adjust the energy intake to their necessities, 
in order to allow the correct development, as 
children and adolescents are in a period of 
constant changes, both physical and 
psychological. Thus, providing an adequate 
nutrition, to allow the child to reach his full 
development potential is essential7,9,11. The 
traditional recommendations are, usually, 
overestimated in obese, due to the 
decreased physical activity, and should be 
adjusted9. 
The first approach in obese children and 
adolescents is to reduce the usual nutritional 
mistakes. Over the last decades it has been 
observed a trend to increase the caloric 
density of foods, the percentage of fat and 
carbon hydrates (CH), and to reduce the 
content of micronutrients and fibers. Thus, 
there is an absolute and relative increase in 
fat and CH intake. It is known that skipping 
breakfast increases the incidence of obesity 
and decreases school performance17. Other 
common mistakes include an excessive 
amount of candies and pastries as snacks, 
and an excessive intake of soft drinks with a 
high concentration of CH5,7,9. The substi-
tution of this type of snacks by other 
healthier options, e.g. fruits, is beneficial8. 
Not only the type of food is inadequate, 
but also the number of meals, the daily 
energy distribution, the serving sizes and 
their weekly basis8,9. In western cultures 
there is an excess of meat intake, especially 
red meat, with a reduction of fish based 
meals. The intake of meat should be reduced 
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to 3 times a week, preferably lean meat (e.g. 
turkey, chicken), and the intake of fish 
should be of at least of 2-3 meals per week9. 
Fruit and vegetables intake usually do not 
reach the recommended 4-5 portions per 
day6,9 and the consumption of whole grains is 
also reduced9. Due to the reduced intake of 
fruits, vegetables and cereals there is a lower 
intake of fibers, a macronutrient that is 
associated with the reduction of obesity and 
with other beneficial effects, as the 
regulation of intestinal function and reducing 
the risk of colon-rectal cancer9. In adoles-
cents, the importance of alcohol ingestion in 
the energy balance should be considered9. 
Other healthy changes in food habits 
include the reduction of serving sizes and the 
increase in the time reserved for meals as, by 
prolonging the length of the meal, there is an 
increase in satiation through the release of 
anorexigenic and satiation mediators, as 
some gastro-intestinal peptides (e.g. Y 
peptide)8. 
The way food is prepared is important to 
stimulate children to eat healthy. Cooking 
with less fat and the substitution of frying by 
grilling and baking help to reduce fat 
intake7,9. It is also important to reduce the 
use of oil and industrial sauces (e.g. 
mayonnaise, ketchup). The use of salt should 
be limited, as many of the obese children 
have increased BP; aromatic herbs are a 
good substitute. Food presentation should 
not be forgotten, as it motivates children to 
eat better and forget that they are in a diet, 
if that is the case9. 
The majority of the diets target changes 
in the amount and percentage of 
macronutrients. When the approach to 
reduce nutritional mistakes in overweight 
and moderated obesity is not successful, a 
nutritionist can prescribe a hypocaloric diet, 
with the reduction of daily energy intake of 
about 30%. A balanced hypocaloric diet 
might also involve the increase in fiber 
intake, the reduction of CH with high 
glycemic levels and the substitution of 
saturated by mono and poly-unsaturated 
fats7,9. Hypocaloric diets and low CH diets 
have shown similar results in short term 
studies8. 
In the last years a great number of fast 
diets and supplements have become 
available to help weight loss. The scientific 
data supporting these treatments are scanty 
and they should not be used by pediatric 
patients. Adolescents are a particular 
vulnerable group due to their autonomy to 
make some decisions8. 
To help children learn the best nutritional 
options, different strategies have been used, 
as the traffic light diet. In this diet the foods 
are classified according to their content in 
fat. The foods labeled green are low in fat 
and could be consumed freely, while the 
consumption of food of the red group, high 
in fat, should be limited. Similar campaigns 
have been used in Portugal with interesting 
results8. 
When a weight-losing diet is followed, 
besides the decrease in fat mass, a decrease 
in lean mass also occurs. Thus, it is important 
to add protein sources of high biological 
value to the diet and to increase physical 
exercise levels, in order to maintain and 
improve the lean mass throughout the diet9. 
In overweight and moderately obese 
younger children the main objective is to 
maintain the body weight without 
compromising the normal body deve-
lopment, as the BMI, usually normalizes with 
height increase7,9. Also, the energy restriction 
should be moderate, in a way that it can be 
sustained in time8. Very low caloric diets 
(500-600 kcal/day) and the use of liquid 
formulas to substitute entire meals should 
not be used in children and adolescents, and 
are only recommended in cases of increased 
health risk and morbid obesity9. In fact, some 
centers specialized in the treatment of 
morbidly obese or obese with comorbidities 
have successfully used that approach (8). 
These diets need special attention to avoid 
the development of acidosis, through an 
adequate CH intake, and to prevent the 
extensive loss of lean mass, by controlling 
the protein ingestion8,9. 
 
BIOCHEMICAL OUTPUTS OF DIET 
Diet restriction is associated with 
improvements in adiposity and in lipid 
profile, namely a reduction in total 
cholesterol (TC) and low density lipoprotein 
cholesterol (LDLc). The influence of diet in 
high density lipoprotein cholesterol (HDLc) 
and triglycerides (TG) appears to be limited, 
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presenting physical exercise more 
pronounced effects18. This fact might be 
explained by a small impact of diet on insulin 
resistance (IR)18. 
An improvement in inflammation, 
following diet-induced weight loss has also 
been reported. In fact, following a diet 
restriction program, total adiponectin levels 
(an anti-inflammatory mediator) were incre-
ased, while inflammatory mediators such as 
leptin, interleukin (IL)-15, and IL-18, were 
reduced19,20. A cumulative effect of diet and 
physical exercise on the improvement of the 
inflammatory status was reported19, howe-
ver, there are conflicting results20. 
The use of specific components in the 
diet, besides the energy restriction, might 
lead to different outcomes regarding 
metabolic changes. The different types of 
fats, for instance, are associated with 
different effects. Increased fat intake is 
associated with a reduction of adiponectin21, 
while children receiving n3 fatty acids 
supplementation presented an improvement 
of the inflammatory status (increased 
adiponectin and reduced TNF-a and leptin). 
The improvement in inflammation is proba-
bly on the basis of the reduction in IR22. 
The type of diet recommended, its caloric 
content, and individual components should 
be defined according to the individual degree 
of obesity, presence or not of comorbidities 
and specific metabolic risk profile, in order to 
obtain the expected benefit from it. 
 
PHYSICAL ACTIVITY 
Southern European countries, including 
Portugal, present lower physical activity 
levels, among children and adolescents, than 
countries from Central and Northern Europe. 
Part of the increased prevalence of obesity in 
the Southern countries might be related to 
this fact23. 
An inadequate energy intake accom-
panied by reduced physical activity is very 
likely to result in weight excess. An increase 
of the physical activity levels is mandatory in 
obesity treatment and has multiple benefits. 
To achieve an improvement, two points 
should be considered: to reduce the time 
spent on sedentary behaviors and to increa-
se physical activity levels. 
The daily energy expenditure is calculated 
by the sum of the energy expended in rest, 
the diet induced thermogenesis and the 
energy expended on physical activities9. 
Strategies and interventional programs to 
increase the physical activity among pediatric 
populations have flourished in the last years. 
School based programs might be particularly 
interesting as they take advantage of 
children availability and school sports 
equipment5,9. However, programs involving 
physical exercise should choose stimulating 
and new activities, especially for the younger 
children, as their interest is harder to 
maintain7,11. The simple increase of the hours 
spent on curricular physical exercise do not 
present significant improvements11. 
The guidelines for physical activities in 
children and adolescents state that 30 to 60 
min a day should be dedicated to moderate 
or intense physical activity5,6,9,11. Physical 
activities should be adequate for age and 
gender. The general recommendations have 
to be adjusted for each children and the 
exercise plan adequate to their socio-
cultural-economic background5-7, 9,11. 
Increasing activity levels with everyday 
activities, as gardening, walking to school, 
riding a bicycle and traditional children 
games, as hide and seek, might be effective 
in increasing the metabolic level and should 
be encouraged7,8,11. On the other hand, 
sports groups, although helpful, may not 
provide enough activity, due to the limited 
training period, weekly schedule, and the 
fact that level of engagement in the exercise 
vary between individuals7,11. The use of 
accelerometers is a good option for objecti-
vely control the level of physical activity, 
even during entire days. Its use has, 
however, considerable financial costs6. 
Moreover, the ingress in a sport group of 
an unfit obese child should be done carefully 
as an initial incapacity to perform requested 
exercises could lead to demotivation and an 
eventual bulling by the peers, what could 
cause the child to withdraw. Thus, group 
sports could be post-poned until the patient 
has reached minimum skills7,11. 
There are conflicting results regarding the 
success of interventional programs involving 
exercise alone or combined with diet. Doubts 
exist, particularly regarding the long term 
effectiveness on weight maintenance9,11. 
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Further studies on the influence of less 
“aggressive” programs following (e.g. a 
motivational approach towards the 
improvement of lifestyle habits) would be 
important12. 
Regarding sedentary behaviors, such as 
screen time, parents should define the 
period of duration and its content, while 
outdoor playing should be encouraged, if 
safeness is granted8. 
Once again, each obese individual is a 
particular case and should be addressed in 
that way. 
The child should be challenged and 
motivated to increase physical activity 
gradually and to achieve realistic goals. 
Unpleasant situations should be avoided. 
 
BIOCHEMICAL OUTPUTS OF PHYSICAL 
EXERCISE 
An adequate performance of physical 
exercise presents several beneficial effects. 
For instance, there is an improvement of the 
lipid profile, with the reduction of TG and the 
increase of HDLc. A key factor underlying this 
improvement seems to be the increase in 
insulin sensitivity that follows the increased 
physical fitness. In fact, the improvement of 
the hepatic insulin sensitivity is associated 
with changes in the lipoproteins produced by 
this organ towards the production of a less 
atherogenic profile24-27. Nevertheless, there 
are still some contradictory results28. Diet, on 
the other hand, seems to have limited 
impact on HDLc and insulin sensitivity18. 
The increase in regular physical activity is 
also associated with an improvement of the 
inflammatory status, with the reduction of 
inflammation markers, such as IL-6, CRP, 
leptin and TNF-a28-3 and the increase in 
anti-inflammatory adiponectin32,33. In fact, 
the exercise-related improvement in IR is 
likely to be associated with this 
enhancement of the pro/ anti-inflammatory 
balance34,35. However, there are still some 
controversies regarding changes in 
inflammatory mediators levels with physical 
exercise and weight loss, particularly on 
which markers vary and in the extent of the 
modification36-38. 
The variation in the training protocol used 
in an intervention program can lead to 
different results. Although both aerobic 
training (AT) alone, and aerobic combined 
with resistance training (ART) improved 
adiposity  measures, as BMI, BMI z-score, 
visceral fat and subcutaneous fat, and were 
effective in reverting MS in obese individuals, 
the improvement achieved with ART were 
bigger than with AT39. 
Cardiorespiratory fitness (CRF) is inversely 
associated with CVD risk markers and total 
mortality40, and one of the main 
determinants of the physical activity levels in 
children and adolescents23. In fact, a lower 
CRF is related to increased sedentary beha-
viors and weight gain41. Although CRF has a 
considerable genetic background, it increases 
with exercise23. The use of training protocols 
aiming to increase CRF, as well as the use of 
CRF as an outcome of exercise programs, 
might be a good strategy to control the 
effectiveness of interventional programs. 
Some studies suggest that improvements 
in IR, lipid profile (e.g. HDLc) and 
inflammatory status are only present in the 
case of a substantial improvement in BMI 
(e.g. a reduction of BMI z-score > 0.5)30,31,42, 
while others state that even moderate 
reductions are already characterized by 
improvements12. 
Besides the weight reduction that might 
accompany the increase in physical exercise, 
a key factor to explain the metabolic changes 
that occur, are the changes in the body 
composition, particularly the reduction in 
central adiposity, known to be associated 
with worsening of the risks factors for CVD43-
45. Thus, some of the conflicting results 
regarding the effects of physical exercise and 
diet on metabolic parameters might be 
related to the effective changes in body 
composition. More than considering only 
changes on weight or BMI to evaluate the 
success of an interventional program, the 
analysis of markers of adiposity distribution, 
such as waist circunference, waist 
circunference-to-height ratio, skin folds and 
DEXA, would be a better option. 
Study the impact of small reductions of 
adiposity on CVD risk markers would be 
important. Smaller improvements might be a 
more realistic target, which could be more 
easily achieved and sustained, avoiding the 
loss of motivation in longer, stricter 
programs. 
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PHARMACOLOGICAL STRATEGIES 
Pharmacological strategies to improve 
weight loss in pediatric obese patients have 
been proposed. Nevertheless, these 
strategies must be always an adjuvant to 
lifestyle changes, including diet and 
increased physical exercise. The weight loss 
obtained by the use of drugs is, usually, small 
but significant5,9,46. 
The use of an adjuvant pharmacologic 
therapy should be considered carefully and 
in specific cases, when the relation 
risk/benefit is favorable. Patients that could 
be considered for pharmacological therapy 
include obese individuals that do not 
respond to behavioral treatments or present 
comorbidities, and overweight children 
presenting comorbidities. Overweight or 
obese children with a strong family history of 
T2DM or CVD should also be considered, 
even when comorbidities are not 
present5,9,46. 
The drugs used have specific actions and 
can be included in the following groups: 
drugs reducing energy intake (anorexigenics), 
drugs that interfere with dietary nutrients 
and drugs interfering with the 
metabolism9,46. Table 1 resumes some of the 
drugs that have been studied and/or used in 
pediatric obese patients, their mechanism of 
action and adverse effects. 
In Portugal the only drug approved for the 
treatment of obesity is Orlistat, however it is 
not recommended for children and 
adolescents47-49. 
Other drugs have been used in adults 
with interesting results regarding weight 
reduction, however the information about 
their applicability in pediatrics is limited or 
absent. This list of drugs enclose bupropion 
(antidepressive), lorcaserin (selective 5-HT2C 
receptor agonist), tesofensine (monoamine 
reuptake inhibitor), pramlintide (amylin 
analogue), exenatide and liraglutide (GLP-1 
analogs); other drugs, as acarbose 
(pseudotetrasaccharide), have still limited 
support, even in adults(46). Rimonabant (CB1 
cannabinoid receptor inhibitor), an appa-
rently promising drug, was withdraw due to 
the association with an increased risk of 
suicide idealization and attempt8. 
Another therapeutic option for the 
treatment of obesity, available in Portugal, is 
a medical device called XL-S Medical®. The 
functional component of this device is 
Litramine, a complex of soluble organic and 
vegetal fibers that jellify in the stomach, 
capturing the lipids present in the meal, 
diminishing their absorption, with effects 
similar to orlistat (although the mechanism 
of action is different). Although it doesn’t 
have a pharmacological action, its use in 
individuals under the age of 18 years should 
be done only under the supervision of a 
pediatrician49,50. 
Obesity is a multiorgan pathology, and 
weight control is mediated by a large number 
of mechanisms in the organism. In this way, 
the use of therapies combining different 
drugs, acting by different mechanism, to 
treat or prevent weight gain, such as the 
combination of peripheral and  central  
acting drugs, can enhance the success of the 
pharmacologic therapy5,46. Some of the 
combinations used in adults are phentermine 
and topiramate (approved by the Food and 
Drugs Administration (FDA) for the 
treatment of obesity in adults, in 2012), 
bupropion and naltrexone (recommended 
for approval by FDA Metabolic Drugs 
Committee), amylin and leptin analogues, 
and pramlintide and phentermine or 
sibutramine46. None of these combinations 
are available in Portugal47-49. 
The use of pharmacologic treatment 
should always be considered with caution, 
particularly in pediatric patients, and faced 
as adjuvant of lifestyle modification 
strategies. Nevertheless, it should not be a 
taboo and, when a positive risk benefit 
balance is considered, the use of drugs can 
be a helpful tool. Portuguese and European 
regulatory agencies have adopted a 
particularly restrictive position towards 
possible pharmacological options, parti-
cularly when compared to the USA’s FDA. As 
a direct consequence, off-label use is a 
growing reality in obese treatment. More 
flexible legislation and clearer guidelines 
would probably guarantee the safety and 
efficacy of obesity treatments. When 
considering the pros and cons of 
pharmacological options it is important to 
consider not only the comorbidities 
presented by the patient, but also the risk for 
future obese-related complications. Thus, 
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the balance between the benefits and risks 
of controlling adiposity, especially in young 
ages, is very important, as obesity is a 
chronic condition that tracks into adulthood. 
Moreover, the drugs to treat obesity, both in 
adults and in children, have to demonstrate 
long-term safety and efficacy, particularly 
when treatment is started in pediatric 
ages5,46. 
 
SURGICAL TREATMENT AND OTHER 
OPTIONS 
Surgical treatment in obese children and 
adolescents is controversial and the last 
therapeutic option, used only when the 
traditional approaches failed. It might be 
considered in case of extreme obesity 
(BMI>40kg/m2) with associated comorbi-
dities (hypertension, dyslipidemia, IR, non-
alcoholic fatty liver disease (NAFLD)), and in 
case of BMI>35kg/m2 with associated serious 
comorbidities (T2DM, sleep apnea, endo-
craneal hypertension or serious NAFLD)8,9,11. 
Moreover, as adolescents are still in 
development, bariatric surgery should be 
carefully considered. The recommendations 
for bariatric surgery include: 
● A minimum Tanner stage of 4 or 5. 
Less mature individuals could be 
considered if severe comorbidities are 
present; 
● Have reached at least 95 % of growth 
potential, especially if malabsorptive 
surgery is considered; 
● Psychological maturity and capacity to 
understand the limitations that will 
follow the procedure: 
● Dietary and activity changes; 
● Family and social support; 
● Exclusion of genetic or syndromic 
obesity6-8; 
● Failure of lifestyle intervention, with a 
duration of at least 6 months8. 
Bariatric surgery is also contraindicated in 
adolescents with history of alcohol or drug 
abuse in the last year, pregnant or planning 
to get pregnant in the next 2 years, and in 
patients who did not correctly followed 
previous lifestyle treatment7. 
The most relevant bariatric techniques in 
pediatric obesity are gastric bypass, gastric 
banding and gastric balloon. 
The gastric bypass in Y of Roux, due to its 
malabsorptive and restrictive nature, is one 
of the most used surgical options in obesity. 
In fact, it is the most used technique in the 
USA. This surgery consists of a reduction of 
stomach size and a reduction of intestinal 
absorptive capacity via the creation of a 
gastrojejunal anastomosis6,8. The gastric 
bypass allows the loss of 50-60% of the body 
weight, as well as improvements in several 
metabolic parameters, such as TG, TC and 
IR6,8,9,11. Side effects involve nutritional 
deficiencies, due to malabsorption. Patients 
submitted to this surgery need to be 
followed by a multidisciplinary team, 
including doctors, psychologists and nutria-
tionists before and after surgery6,  9,11. 
The gastric banding is a less invasive 
surgical technique, when compared to 
gastric bypass. This option has increasing 
acceptance nowadays, due to its reversibility 
and lower number of side effects. The gastric 
banding is, in fact, the most used bariatric 
surgery in Europe for the treatment of obese 
adolescents, presenting a considerable 
success. It consists in the laparoscopic 
placing of a silicon ring around the proximal 
part of the stomach that will limit food 
ingestion. This ring can be regulated by 
introducing saline in a subcutaneous reserve-
tory. However, the weight reductions are 
more limited than with gastric bypass, 
reaching around 20-30%, the side effects, as 
malabsorption, are less frequent and have 
less impact in the development of the 
adolescents6,7,9. 
The endoscopic implantation of a gastric 
balloon is the lowest invasive option, when 
compared to the other two. Similarly to the 
gastric banding this is a reversible technique 
with lower number of side effects. Achieved 
weight reductions are comparable to those 
obtained with the gastric banding (20 - 30% 
of weight reduction)6-9. 
The temporary nature of the gastric 
balloon, and the reversibility of gastric ban-
ding, come with the common problem of 
weight rebound, once the balloon or the 
banding are  removed. A multidisciplinary 
team with psychologists and dietitians, 
beside pediatricians, need to follow the 
patient, before and during the whole 
process, with particular attention after the 
removal of the restrictive device7. 
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CONCLUSION 
Pediatric obesity is a public health 
problem. It is associated with increased risk 
of CVD in adulthood, besides other 
comorbidities that are present already in 
early ages, greatly affecting the quality of 
life. An adequate intervention in these ages, 
when healthy habits are more likely to be 
acquired and kept is, thus, crucial. 
In fact, the literature presents a consi-
derable amount of studies regarding the 
intervention on pediatric obesity, with 
varying results. Part of this variation could be 
explained by different study designs and 
population. 
Nevertheless, changes in lifestyle, with 
the increase in physical activity levels and a 
healthier diet, are associated with improve-
ments in cardiovascular risk factors, namely 
lipid profile, IR and inflammation. 
The combination of diet and exercise in 
the same intervention appear to be 
beneficial. However, different types of diet 
and exercise might lead to different results. 
The use of pharmacological adjuvants in 
pediatric obesity treatment is very limited in 
clinical practice due, mainly, to the lack of 
adequate studies; however some options 
have demonstrated to contribute to a small, 
but consistent, improvement in adiposity. 
Surgery, on the other hand, is the last 
therapeutic option and should be considered 
only in the more severe cases. 
Obese children and adolescents would 
benefit from the development of a scienti-
fically based standard protocol, involving 
changes in physical exercise levels and diet, 
through a behavioral approach. This protocol 
should be adapted to each individual cultural 
and socioeconomic background. 
Governments, including the Portuguese, 
have been paying more attention to this 
issue in the last years.  However, much more 
can be made in general policies to create a 
less obesogenic environment and make the 
healthy choices the easier ones. 
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Table 1. Pharmacological options for obesity treatment
 
Drug Mechanism  of action Side effects 
 Centrally acting anorexigenic  
Phenterminea and diethylpropiona46-49 
Anorexogenic effects by increasing adrenergic tone, 
decreasing energy intake and increasing resting energy 
expenditure 
Euphoria, palpitations, hypertension, cardiac 
arrhythmias, dizziness, blurred vision and abuse 
potential. 
Fluoxetine, chlorphentermine1, 
fenfluramineb and dexfenfluramineb 46-49 
Reduces appetite by increasing serotonergic release or 
inhibiting re-uptake 
Cardiac valvulopathies, increased risk of primary 
pulmonary hypertension, headache, abdominal pain, 
drowsiness, insomnia, dry mouth, increased activity and 
irritability 
Methylphenidate  and 
dextroamphetamine1 46-49 
Anorexogenic effect by inhibiting dopamine reuptake 
Agitation, insomnia, tachycardia, hypertension, 
hyperhidrosis and abuse potential 
Sibutramine2 5,6,9,11,46-49 
Inhibits serotonin, norepinephrine and dopamine 
reuptake, presenting an anorexogenic effect and 
increasing energy expenditure 
Cardiovascular events (myocardial infarction and 
stroke), hypertension, increased heart rate, headache, 
dry mouth, anxiousness, insomnia, depression, 
constipation and  cholelithiasis 
Leptinaa,c 9,11,46-49 
Transmits information to hypothalamic centers of the 
adipocyte lipid reserves and of nutrients and energy of 
meals – satiation effect 
Increased inflammation 
Topiramate5,9,46-49 Anorexogenic effects by GABA-ergic stimulation 
Psychomotor disturbances, difficulties with 
concentration, sedation, reduction of learning skills, 
paresthesias and taste impairment. 
 Drugs affecting dietary nutrients  
Orlistatd 5,6,9,11,46-49 
Inhibits gastrointestinal and pancreatic lipases, reducing 
the absorption of ingested dietary fats 
Intestinal gases, oily stools, oily spotting, oily evacuation, 
abdominal pain, fecal urgency, diarrhea and gallstones. 
Lipid soluble vitamins deficiency. 
 Drugs affecting the metabolism  
Metformin5,6,9,11,46-49 
Modulation of insulin action. Inhibits intestinal glucose 
absorption, reduces hepatic glucose production and 
increases peripheral insulin sensitivity by improving 
glucose uptake and utilization 
Diarrhea, nausea, vomiting and flatulence. Vitamin B12 
and folic acid deficiency 
Octreotidee 5,46-49 
Modulation of insulin action. Octreotide inhibits the 
release of the growth hormone, thyrotropin and 
corticotropin from the hypophysis; and of insulin and 
glucagon from the pancreas and ghrelin from the stomach. 
Transient elevation of blood glucose, diarrhea, 
abdominal pain, discomfort, flatulence influenza-like 
symptoms, constipation, headache, fatigue, dizziness, 
nausea, anemia, hypertension, and gallstones 
Growth hormonef 5,46-49 
Modulation of lipolysis. Inhibits LpL, increases hormone-
sensitive lipase levels and stimulates lipolysis in adipocyte, 
stimulates protein synthesis and increased fat-free mass 
Increased risk of tumor, potential adrenal insufficiency, 
insulin resistance, increased risk of sleep apnea and 
increased cardiac diameter 
Ephedrine combined with caffeinea 46-49 
Modulation of energy expenditure. Ephedrine increases 
catecholaminergic tone while caffeine acts by inhibiting 
phosphodiesterases. Ephedrine presents a thermogenic 
effect that is enhanced with the administration of caffeine 
Cardiac effects, nausea, insomnia, tremor, dizziness and 
palpitations 
a
Not commercially available in Portugal. 
b
Withdraw from Portuguese market. 
c
Used only to treat syndromic obesity related to lack of leptin production., 
c
Only 
pharmacological option approved in Portugal. 
f
Used only for the treatment of patients with hypothalamic obesity. 
f
Used only to treat syndromic obesity characterized by 
reduced synthesis of growth hormone – e.g. Prader Willi Syndrome. 
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